Euroopan unioni - suomi - EMA (European Medicines Agency)

novartis europharm ltd - valsartan, amlodipine (as amlodipine besilate) - verenpainetauti - reniini-angiotensiinijärjestelmään vaikuttavat aineet - essentiaalisen hypertension hoito. imprida on tarkoitettu potilaille, joiden verenpaine ei laske riittävästi yksinomaan amlodipiinilla tai valsartaanilla.

Euroopan unioni - suomi - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. käyttö tämä rokote tulee virallisten suositusten mukaisesti.

Euroopan unioni - suomi - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Euroopan unioni - suomi - EMA (European Medicines Agency)

takeda pharma a/s - azilsartan medoxomil - verenpainetauti - reniini-angiotensiinijärjestelmään vaikuttavat aineet - ipreziv on tarkoitettu aikuisten välttämättömän hypertension hoitoon.

Euroopan unioni - suomi - EMA (European Medicines Agency)

pharmathen s.a. - irbesartaania - verenpainetauti - reniini-angiotensiinijärjestelmään vaikuttavat aineet - sabervel on tarkoitettu aikuisille välttämättömän hypertension hoitoon. se on myös tarkoitettu munuaistaudin hoito aikuisilla potilailla, joilla on korkea verenpaine ja tyypin 2 diabetes osana verenpainelääkityksen.

Suomi - suomi - Fimea (Suomen lääkevirasto)

stada arzneimittel ag - lisinopril - tabletti - 5 mg - lisinopriili

Suomi - suomi - Fimea (Suomen lääkevirasto)

stada arzneimittel ag - lisinopril - tabletti - 10 mg - lisinopriili

Suomi - suomi - Fimea (Suomen lääkevirasto)

stada arzneimittel ag - lisinopril - tabletti - 20 mg - lisinopriili

Suomi - suomi - Fimea (Suomen lääkevirasto)

sandoz a/s sandoz a/s - valsartanum,hydrochlorothiazidum,amlodipini besilas - tabletti, kalvopäällysteinen - 5 mg / 160 mg / 12.5 mg - valsartaani, amlodipiini ja hydroklooritiatsidi

Suomi - suomi - Fimea (Suomen lääkevirasto)

sandoz a/s sandoz a/s - hydrochlorothiazidum,amlodipini besilas,valsartanum - tabletti, kalvopäällysteinen - 10 mg / 160 mg / 12.5 mg - valsartaani, amlodipiini ja hydroklooritiatsidi